News & Perspective

Nov 15, 2019

Nov 15, 2019

ASP Scan (Weekly) for Nov 15, 2019

Dental antibiotic stewardship
Host-response diagnostic tests
Antibiotic use, resistance in Europe
Pakistan and typhoid vaccine
Hospital stewardship toolkit
Candida auris in NY hospitals
Antibiotic prescribing drop in Finland
Scottish antibiotic use
Improper antibiotic Rx in Japan
Pre-op antibiotic overuse
Highly lethal Klebsiella strain
FDA antimicrobial guidance
C diff in VA hospitals
UK antibiotic development
ESBL carriage in dogs

May 13, 2014

May 13, 2014

Drug Resistance Scan for May 13, 2014

US/EU drug-resistance efforts
MRSA strains in pets

Jan 23, 2013

Jan 23, 2013

Research moratorium on modified H5N1 viruses ends

(CIDRAP News) – A year-long voluntary moratorium on research involving transmissible H5N1 avian flu viruses ended today with a letter from a group of scientists that supports resuming the work in countries that have addressed the biosafety issues involved.

Dec 13, 2011

Dec 13, 2011

Novartis says cell-based flu vaccine facility ready to produce

(CIDRAP News) – Novartis's new cell-culture based influenza vaccine factory in North Carolina has begun making a prepandemic H5N1 flu vaccine and is ready to start producing vaccines for a real pandemic when needed, the company and federal health officials announced yesterday.

The facility in Holly Springs, N.C., billed as the first of its kind in the United States, was dedicated yesterday after a long testing process.

Nov 24, 2009

Nov 24, 2009

Novartis unveils US cell-based flu vaccine plant

(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.

Oct 23, 2009

Oct 23, 2009

More clouds in H1N1 vaccine supply picture

(CIDRAP News) – Questions about the tardy US supply of pandemic H1N1 vaccine have increased with the report that most of Novartis's doses may not reach the country until early in 2010 and a European regulatory recommendation that may have implications for the global vaccine supply.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»